Skip to content

MAKING BEST PRACTICE, EVERYDAY PRACTICE

FREE accredited digital CPD for health care professionals in South Africa

Accredited by the University of Pretoria

MAKING BEST PRACTICE, EVERYDAY PRACTICE

FREE accredited digital CPD for health care professionals in South Africa

Accredited by the University of Pretoria

Menu

Home
About
All clinical topics
SPECIAL INTEREST GROUPS
- Medical interns and registrars
Contact
ACCESS MY PROFILE

Menu

Home
About
All clinical topics
SPECIAL INTEREST GROUPS
- Medical interns and registrars
Contact
ACCESS MY PROFILE

[denovo_breadcrumbs]

Hope on the horizon – Extending access to GLP-1 Receptor Agonists for T2DM patients with chronic obesity

Questionnaire

To access this module, please register or login:

Login or Register

Hope on the horizon – Extending access to GLP-1 Receptor Agonists for T2DM patients with chronic obesity
Hope on the horizon – Extending access to GLP-1 Receptor Agonists for T2DM patients with chronic obesity

Time limit: 0

Questionnaire Summary

0 of 10 Questions completed

Questions:

Information

You have already completed the questionnaire before. Hence you can not start it again.

Questionnaire is loading…

You must sign in or sign up to start the questionnaire.

You must first complete the following:

Results

Questionnaire complete. Results are being recorded.

Results

0 of 10 Questions answered correctly

Time has elapsed

You have reached 0 of 0 point(s), (0)

Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)

Categories

Not categorized 0%

Regrettably, you have failed to achieve the 70% pass mark required by the accrediting HPCSA.
Please read/watch the module carefully and try once more!
(Only two tries are allowed)
Congratulations on successfully completing this FREE CPD module!
- For HPCSA members only: No need to load your certificate on HPCSA, as deNovo Medica uploads these weekly. Please allow 5-10 working days for the CPD activity to reflect on your HPCSA profile
- For non-HPCSA members: The above button allows you to download and print your CPD certificate to submit to your council yourself.
Please note you will no longer receive a pass confirmation email. Your activity automatically downloads on to your deNovo Medica profile.
Visit your profile HERE to find all your CPD certificates and activities completed.

1
2
3
4
5
6
7
8
9
10

Current
Review
Answered
Correct
Incorrect

Question 1 of 10
1. Question
The most common cause of mortality in South African females is:
A. HIV/AIDS
Correct Incorrect Correct answer

B. Tuberculosis
Correct Incorrect Correct answer

C. Diabetes
Correct Incorrect Correct answer

D. Breast cancer
Correct Incorrect Correct answer
Question 2 of 10
2. Question
The GLP-1RA that is most homologous to native GLP-1 is:
A. Exenatide
Correct Incorrect Correct answer

B. Liraglutide
Correct Incorrect Correct answer

C. Semaglutide
Correct Incorrect Correct answer

D. Dulaglutide
Correct Incorrect Correct answer
Question 3 of 10
3. Question
GLP-1RAs exert direct physiological effects on the:
A. Pancreas, liver and muscle
Correct Incorrect Correct answer

B. Liver, stomach and adipose tissue
Correct Incorrect Correct answer

C. Liver, adipose tissue and brain
Correct Incorrect Correct answer

D. Pancreas, brain and stomach
Correct Incorrect Correct answer
Question 4 of 10
4. Question
Compared to men, the risk of developing diabetes in women is more than double when BMI exceeds:
A. 25kg/m2
Correct Incorrect Correct answer

B. 27kg/m2
Correct Incorrect Correct answer

C. 28kg/m2
Correct Incorrect Correct answer

D. 30kg/m2
Correct Incorrect Correct answer
Question 5 of 10
5. Question
Significant weight loss at one year was demonstrated in participants of the SCALE Diabetes trial who received:
A. Liraglutide 1.8mg
Correct Incorrect Correct answer

B. Liraglutide 3.0mg
Correct Incorrect Correct answer

C. Both of the above
Correct Incorrect Correct answer

D. Neither of the above
Correct Incorrect Correct answer
Question 6 of 10
6. Question
Fewer than 20% of patients with T2DM achieve ‘ABC’ control, which is a composite of glycaemic, blood pressure and LDL-C targets.
A. True
Correct Incorrect Correct answer

B. False
Correct Incorrect Correct answer
Question 7 of 10
7. Question
South African data report that in both private and public health sectors and across primary to tertiary healthcare, only half of patients with T2DM achieve HbA_1c <7%.
A. True
Correct Incorrect Correct answer

B. False
Correct Incorrect Correct answer
Question 8 of 10
8. Question
The percentage of liraglutide-treated participants the LEAD programme who achieved HbA1c <7% was:
A. 15-25%
Correct Incorrect Correct answer

B. 30-40%
Correct Incorrect Correct answer

C. 50-60%
Correct Incorrect Correct answer

D. 75-85%
Correct Incorrect Correct answer
Question 9 of 10
9. Question
In terms of target organ damage, T2DM:
A. Increases the risk for developing HF by two-to five-fold
Correct Incorrect Correct answer

B. Increases the probability of cardiovascular death and all-cause mortality by 60-80% in those with established HF
Correct Incorrect Correct answer

C. Is associated with atherosclerotic diseases that account for half of CVD mortality
Correct Incorrect Correct answer

D. All of the above
Correct Incorrect Correct answer
Question 10 of 10
10. Question
Cardiovascular risk factors for which beneficial effects of GLP-1RA therapies have been reported include:
A. SBP, total cholesterol and body weight
Correct Incorrect Correct answer

B. Body weight, but not SBP nor total cholesterol
Correct Incorrect Correct answer

C. SBP and total cholesterol, but not body weight
Correct Incorrect Correct answer

D. Body weight and total cholesterol, but not SBP
Correct Incorrect Correct answer

All Rights Reserved 2025 © deNovo Medica (Pty) Ltd in South Africa. The content on this website is intended for healthcare related professionals unless stated otherwise.

Get involved

Become a sponsor Become a medical partner author/reviewer/society

Get involved

Become a sponsor Become a medical partner author/reviewer/society

Login

Accessing this module requires a login. Please enter your credentials below!

Username or Email Address

Password

Remember Me

Lost Your Password?